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In mice, a selective decontamination of the digestive tract regimen consisting of orogastric tobramycin,
polymyxin E, and amphotericin B in combination with subcutaneous cefepime inhibited gram-negative bacilli,
including Klebsiella pneumoniae, and did not promote vancomycin-resistant Enterococcus spp. (VRE) coloniza-
tion. However, concurrent administration of subcutaneous ampicillin-sulbactam resulted in promotion of VRE.
Selective decontamination of the digestive tract (SDD) is an
infection prophylaxis strategy used in critically ill patients that
is intended to inhibit colonization by aerobic gram-negative
bacilli and fungi while preserving the anaerobic microflora (1,
4). SDD regimens typically include topical oropharyngeal and
enteral nonabsorbed antimicrobials (usually tobramycin, poly-
myxin E, and amphotericin B) in combination with parenteral
antibiotics (usually cefotaxime) for the first few days (1). In a
recent prospective study conducted in The Netherlands, SDD
prophylaxis was associated with significant reductions in mor-
tality, length of stay, and overall antibiotic costs (1). Although
these results are promising, there is concern that SDD regi-
mens could promote colonization by gram-positive pathogens
such as vancomycin-resistant enterococci (VRE) and methicil-
lin-resistant Staphylococcus aureus in intensive care units
where these pathogens are endemic. In fact, the cefotaxime
component of SDD regimens has been shown to promote
overgrowth of indigenous enterococci in the intestinal tract
(11, 14), and we have shown that this agent promotes over-
growth of VRE in mice (our unpublished data). In anticipation
of an upcoming clinical trial of SDD in our organ transplant
intensive care unit, we used a mouse model to examine the
effect of SDD on the establishment of intestinal colonization
by VRE and Klebsiella pneumoniae. Cefepime was substituted
for cefotaxime as the systemic agent because it is minimally
excreted into bile, causes minimal disruption of the anaerobic
intestinal microflora of mice and humans, and does not pro-
mote VRE colonization in mice (4).
The isolates used were VRE strain C68, a clinical VanB
isolate, and K. pneumoniae strain P62, a bloodstream isolate
that produces an SHV extended-spectrum beta-lactamase (4,
7). The test strains have been used in several previous mouse
studies and persistently colonize the intestinal tract when an-
tibiotic selective pressure is maintained (2, 4). A VanB-type
VRE isolate was selected for our prior mouse studies because
these were the predominant VRE strains present in Cleveland
area hospitals in the mid-1990s (2). The effects of antibiotics on
the density and persistence of VRE colonization in mice have
been shown to correlate well with findings in colonized patients
(3). The broth dilution MICs for C68 and P62, respectively,
were as follows: tobramycin, 500 and 32 g/ml; colistin,
10,000 and 0.125 g/ml; cefepime, 10,000 and 0.75 g/ml;
cefotaxime, 10,000 and 4 g/ml; and ampicillin, 256 and
256 g/ml.
The experimental protocol was approved by the Cleveland
Veterans Affairs Medical Center’s Animal Care Committee.
Female CF1 mice (Harlan Sprague-Dawley, Indianapolis,
Ind.) weighing 25 to 30 g were housed individually. Initial
experiments were performed to assess the effect of SDD on the
indigenous intestinal microflora (n  4 mice per group). The
SDD regimen included tobramycin, polymyxin E, and ampho-
tericin B given by orogastric gavage once daily for 5 days and
cefepime given subcutaneously once daily for the first 2 days.
Tobramycin and polymyxin E were given at three times the
usual human dose (in milligrams per kilogram of body weight)
and amphotericin and cefepime were given at the usual human
dose (0.42, 0.51, 0.86, and 2 mg/day for each drug, respec-
tively); Speekenbrink et al. (11) found that this dosage adjust-
ment for tobramycin and polymyxin E was necessary to main-
tain inhibition of facultative gram-negative bacilli in mice.
Fresh stool samples were diluted in saline and plated onto
Enterococcosel agar, MacConkey agar, brucella agar, and Bac-
teroides bile-esculin agar (Becton Dickinson) to measure con-
centrations of enterococci, total and facultative gram-negative
bacilli, total anaerobes, and Bacteroides spp., respectively. Cul-
tures of total anaerobes and Bacteroides spp. were performed
inside an anaerobic chamber (Coy Laboratories). The concen-
trations of antibiotics in stool were determined by an agar
diffusion assay with Escherichia coli as the indicator strain (10).
The lower limits of detection were 2.5 log10 CFU/g of stool.
A second set of experiments was performed to examine the
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effect of SDD on colonization with VRE and K. pneumoniae.
The treatment groups included saline controls, SDD for 5 days,
SDD for 5 days plus ampicillin-sulbactam subcutaneous daily
for 2 days prior to beginning SDD, and ampicillin-sulbactam
subcutaneous for 2 days. Ampicillin-sulbactam was included
because this is the standard perioperative prophylaxis given in
our liver transplant population. Mice received orogastric inoc-
ulation of 10,000 CFU of VRE C68 and K. pneumoniae P62 on
day 2 of the SDD regimens. The organisms were suspended in
0.5 ml of phosphate-buffered saline and administered using a
stainless steel feeding tube (Perfektum; Popper & Sons, New
Hyde Park, N.Y.). The densities of VRE and ceftazidime-
resistant gram-negative bacilli in stool were measured at base-
line and on days 1, 3, and 6 after orogastric gavage as previ-
ously described (7). Two runs of experiments with four mice
per group were performed (i.e., eight total mice/group).
Because higher doses of tobramycin have been shown to
disrupt the anaerobic microflora (9), a third set of experiments
was performed to assess the effect of higher doses of SDD
antibiotics on establishment of VRE colonization (n  4 mice
per group). The treatment groups included saline controls,
orogastric tobramycin plus polymyxin E daily with both agents
at 12 times the usual human dose (1.68 and 2.04 mg/day,
respectively), and subcutaneous cefepime at 12 times the usual
human dose (24 mg/day). The adjustment to 12 times the usual
human dose is based on human equivalent doses calculated by
the technique of Freireich et al. (5); human equivalent doses
are administered to mice when similar serum levels of drugs
are desired. The treatments were continued for 5 days, and
mice received orogastric inoculation of 10,000 CFU of VRE
C68 on day 2 of treatment.
Because cefotaxime has been used in most previous SDD
studies, we performed a final set of experiments to confirm our
previous unpublished observation that this agent may promote
VRE colonization to a greater extent than cefepime. Mice
(n  6 per group) received saline, cefepime (2 or 24 mg/day),
and cefotaxime (3 or 36 mg/day) for 5 days and received oro-
gastric inoculation of 10,000 CFU of VRE C68 on day 2 of
treatment.
Data analyses were performed with the use of Stata software
(version 6.0; Stata, College Station, Tex.). A one-way analysis
of variance was performed to compare the groups with P values
adjusted for multiple comparisons using the Scheffe correction.
For the assessment of the effect of SDD on the intestinal
microflora, Student’s t test was used to compare mean densities
during treatment with baseline densities.
Figure 1 shows the effect of the SDD regimen on the stool
microflora. Densities of total anaerobes and Bacteroides spp.
were not reduced during SDD treatment (P  0.18). Faculta-
tive gram-negative bacilli were reduced to undetectable levels
during treatment, and only one of four mice had detectable
FIG. 1. Effect of the SDD regimen (orogastric tobramycin, poly-
myxin E, and amphotericin B daily for 5 days from day 0 through day
4 plus subcutaneous cefepime for the first 2 days) on the densities of
total anaerobes, Bacteroides spp., facultative gram-negative bacilli, and
Enterococcus spp. in the stool of mice. Stool samples were collected
and plated onto selective media to determine bacterial densities. If
organisms were not detected in stool, the lower limit of detection
(2.5 log10 CFU/g) was assigned. Error bars represent standard errors.
FIG. 2. Effect of the SDD regimen on the establishment of intestinal colonization with VRE (A) and extended-spectrum -lactamase-
producing K. pneumoniae (B). Mice received the SDD regimen described in the Fig. 1 legend daily for 5 days (final orogastric dose on day 3) and
received 104 CFU of VRE and K. pneumoniae by orogastric inoculation on day 0. Subcutaneous ampicillin-sulbactam was administered to the
indicated mice daily for 2 days prior to beginning the SDD regimen. Stool samples were collected and plated onto selective media to determine
the densities of the two pathogens. If the pathogens were not detected in stool, the lower limit of detection (2.5 log10 CFU/g) was assigned. Amp,
ampicillin. Error bars represent standard errors.
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levels 2 days after discontinuation of treatment (i.e., day 6 in
Fig. 1). The level of enterococci was significantly reduced on
day 3 in comparison to pretreatment levels (P  0.005). The
mean concentration of tobramycin in stool was 125 g/g,
whereas cefepime was not detectable (limit of detection, 1
g/g). Polymyxin E could not be measured using the bioassay
because it did not diffuse into agar (i.e., no zones were appar-
ent in the control wells containing known concentrations of
antibiotics).
Figure 2 shows the effect of the treatment regimens on the
establishment of colonization with VRE (Fig. 2A) and K. pneu-
moniae (Fig. 2B). At baseline, the mice did not have detectable
VRE or ceftazidime-resistant gram-negative bacilli in stool.
Ampicillin-sulbactam promoted overgrowth of VRE and K.
pneumoniae (P of0.001 in comparison to saline controls); the
addition of the SDD regimen inhibited ampicillin-sulbactam-
associated overgrowth of K. pneumoniae (P of 0.999 in com-
parison to saline controls). The SDD regimen and the
cefepime component of the regimen did not promote over-
growth of either pathogen (P of 0.94 in comparison to saline
controls).
Figure 3 shows the effect of the higher doses of SDD anti-
biotics on the establishment of colonization with VRE. High-
dose tobramycin plus polymyxin E promoted overgrowth of
VRE (P of 0.046 in comparison to saline controls), whereas
high-dose cefepime did not (P  0.99).
Figure 4 shows the effect of cefotaxime versus cefepime on
the establishment of colonization with VRE. Cefotaxime pro-
moted overgrowth of VRE in comparison to saline controls (P
of 0.043 for the lower dose and P of 0.001 for the higher
dose), whereas cefepime at either dose did not (P  0.88).
In summary, we found that the SDD regimen including
parenteral cefepime inhibited gram-negative bacilli but did not
suppress total anaerobes or Bacteroides spp. and did not pro-
mote VRE colonization. In contrast to cefotaxime, cefepime
monotherapy did not promote the establishment of VRE col-
onization even when administered at 12 times the usual human
dose. The absence of promotion of VRE by cefepime is likely
to be in part related to the fact that minimal amounts of this
antibiotic are excreted into the bile of mice or humans in
comparison to amounts associated with other extended-spec-
trum cephalosporins (i.e., 0.16% of subcutaneously adminis-
tered cefepime was estimated to be excreted into the intestinal
tracts of mice versus 3% of ceftazidime and 11.1% of ceftriax-
one) (4, 13). Our findings suggest that substitution of cefepime
for cefotaxime in SDD regimens could offer the benefit of
causing less alteration of colonization resistance. However,
ampicillin-sulbactam treatment for 2 days (i.e., the standard
perioperative prophylaxis used in our liver transplant patients)
promoted overgrowth of VRE with or without concurrent
SDD. Others have similarly observed that the benefit of SDD
regimens may be reduced if antibiotics that disrupt the anaer-
obic microflora are given concurrently (6, 8).
Our findings have important implications for future clinical
studies of SDD in our institution and in other U.S. hospitals
with high rates of VRE. One strategy to prevent the over-
growth of gram-positive pathogens in our transplant patients
would be to alter the regimen used for perioperative prophy-
laxis. Alternatively, an oral nonabsorbed agent with activity
against gram-positive pathogens could be added to the SDD
regimen. However, this strategy could result in nonselective
decontamination because agents such as ramoplanin and bac-
itracin may disturb the anaerobic microflora and promote
overgrowth of gram-negative bacilli (12; also unpublished
data). Finally, some caution should be indicated for clinical
trials of SDD in the United States, because the higher doses of
tobramycin plus polymyxin E did promote VRE colonization
in mice.
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